Immune approaches in tuberculosis therapy: A brief overview

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 381-389

  Bourinbaiar, Aldar S ^a   Mezentseva, Marina V ^b   Butov, Dmitry A ^c   Nyasulu, Peter S ^d   Efremenko, Yuri V ^e   Jirathitikal, Vichai ^a   Mishchenko, Vladimir V ^f   Kutsyna, Galyna A ^g  

^a Immunitor Inc   (Canada)

^b GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

^c KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Lisichansk Regional Tuberculosis Dispensary ^*  (Ukraine)

^f CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^g Lugansk State Medical University   (Ukraine)

Author keywords

AIDS; antibody; autoimmune; cytokine; HIV; immunomodulator; inflammation; lung; multidrug resistant TB; mycobacterial; pulmonary; therapeutic vaccine; tubercle bacillus; tuberculin

Indexed keywords

AMIKACIN; AMIKSIN; AZOXIMER BROMIDE; BACTERIAL VACCINE; BESTIM; CYCLOFERON; DZHERELO; GALAVIT; GLUTOXIM; IMMUNOMODULATING AGENT; LIKOPID; NEOVIR; RONKOLEUKIN; UNCLASSIFIED DRUG; V5; V7;

ANTIBACTERIAL ACTIVITY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CHEMOTHERAPY; DRUG EFFICACY; HEMOPTYSIS; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TH1 TH2 BALANCE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULIN; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84858219176     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.1     Document Type: Review

References (66)

1. Erokhin VV, Zemskova ZS. Current views of tuberculosis inflammation. Probl. Tuberk. 3, 11-21 (2003).
2. Dannenberg AM Jr, Collins FM. Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis 81, 229-242 (2001). (Pubitemid 32575231)
3. Cohen J. Shots in the Dark: The Wayward Search for an AIDS Vaccine. W.W Norton & Company, London, UK (2001).
4. Kaufmann SH. Introduction. Rational vaccine development against tuberculosis: "Those who don't remember the past are condemned to repeat it". Microbes Infect. 7, 897-898 (2005). (Pubitemid 40826657)
5. Vilaplana C, Cardona PJ. Tuberculin immunotherapy: its history and lessons to be learned. Microbes Infect. 12, 99-105 (2010).
6. Hoft DF, Brown RM, Belshe RB. Mucosal Bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-g responses. Clin. Infect. Dis. 30(Suppl. 3), 217-222 (2000).
7. Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70, 672-678 (2002). (Pubitemid 34083827)
8. Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 62, 55-62 (1981). (Pubitemid 11177250)
9. Krylov VA, Gergert VIa, Korotkova ED, Kuz'mina NV, Filippov AV. Tuberculin-BCG therapy in combined treatment of patients with pulmonary tuberculosis. Probl. Tuberk. 4, 11-14 (1995). (Pubitemid 26036050)
10. von Reyn CF, Mtei L, Arbeit RD et al. DarDar study group. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24, 675-685 (2010).
11. Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine 11, 795-804 (1993). (Pubitemid 23180236)
12. Radaeva TV, Nikonenko BV, Kapina MA, Mishchenko VV, Apt AS. Experimental approaches to designing vaccines against tuberculous infection reactivation. Probl. Tuberk. 5, 45-48 (2006).
13. Mirzoian EZ. On the method of tuberculin therapy of pulmonary tuberculosis in adults. Probl. Tuberk. 42, 33-38 (1964).
14. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med. 30, 769-782 (2009).
15. Sula L, Radkovský I. Protective effects of M. microti vaccine against tuberculosis. J. Hyg. Epidemiol. Microbiol. Immunol. 20, 1-6 (1976).
16. Zhao GR, Feng DH. A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis. Pharm. J. Chin. PLA 25, 361-364 (2009).
17. Nyasulu PS. Role of adjunctive Mycobacterium w immunotherapy for tuberculosis. J. Exp. Clin. Med. 2, 123-129 (2010).
18. Lei JP, Xiong GL, Hu QF et al. Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhonghua Yu Fang Yi Xue Za Zhi 42, 86-89 (2008).
19. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci. 9, 1701-1719 (2004). (Pubitemid 38918627)
20. Luo Y, Lu S, Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 23, 85-88 (2000).
21. Dlugovitzky D, Notario R, Martinel-Lamas D et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2, 159-169 (2010).
22. Dryer G. Some new principles in bacterial immunity, their experimental foundation, and their application to the treatment of refractory infections, including tuberculosis. Brit. J. Exp. Pathol. 46, 146-176 (1923).
23. Vilaplana C, Montané E, Pinto S et al. Double-blind, randomized, placebo-controlled Phase 1 clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28, 1106-1116 (2010).
24. Arjanova OV, Prihoda ND, Yurchenko LV et al. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J. Vaccines Vaccinat. 1, 103 (2010).
25. Arjanova OV, Prihoda ND, Yurchenko LV et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy 3, 181-191 (2011).
26. Butov DA, Pashkov YN, Stepanenko AL et al. Phase 2b randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J. Immune Based Ther. Vaccines 9, 3 (2011).
27. Arjanova OV, Butov DA, Prihoda ND et al. One-month immunotherapy trial in treatment-failed TB patients. Open J. Immunol. 1, 50-55 (2011).
28. Xu M, Luo Y-a, Chen B-w et al. The study on preventive effect of M. smegmatis vaccine for people infected with M. tuberculosis. Drug Evaluation 2, 1-5 (2006).
29. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr. Pharm. Des. 15, 1238-1247 (2009).
30. Simbirtsev A, Kolobov A, Zabolotnych N et al. Biological activity of peptide SCV-07 (Bestim) against murine tuberculosis. Russ. J. Immunol. 8, 11-22 (2003).
31. Svistunova AS, Pinegin BV, Selitskaia RP et al. The use of immunomodulator likopid in the combined treatment of pulmonary tuberculosis. Probl. Tuberk. 3, 21-25 (2002).
32. Borzenko AS, Antonov YuV, Popkova NL. Use of polyoksidonium in adjunct therapy of patients with pulmonary tuberculosis. Immunologia 2, 41-43 (1999).
33. Knoring BE, El'kin AV, Smirnov MN, Sakharova IYa, Basek TS, Zhuravleva VYu. Immunocorrection of pulmonary tuberculosis with Ronkoleukin. Probl. Tuberk. 5, 26-29 (1999).
34. Mezentseva MV, Stakhanov VA, Zakharova MV et al. Prospects for immunotherapy in adjunct treatment of infiltrating pulmonary tuberculosis. Biopreparaty 2, 20-25 (2011).
35. Zaitzeva SI, Matveeva SL, Gerasimova TG et al. Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin. Microbiol. Infect. 15, 1154-1162 (2009).
36. Arjanova OV, Prihoda ND, Yurchenko LV et al. Enhancement of efficacy of tuberculosis drugs with Immunoxel (Dzherelo) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy 1, 549-556 (2009).
37. Prihoda ND, Arjanova OV, Yurchenko LV et al. Adjuvant immunotherapy of extensively drug-resistant tuberculosis (XDR-TB) in Ukraine. Curr. Res. TB 1, 1-6 (2009).
38. Mezentseva MV, Stakhanov VA, Zakharova MV, Zotova IF, Tregubova MI, Shapoval IM. Cytokines as the markers of the infiltrative pulmonary tuberculosis progress. Infect. Immun. 1, 367-372 (2011).
39. Grange JM, Brunet LR, Rieder HL. Immune protection against tuberculosis -when is immunotherapy preferable to vaccination? Tuberculosis 91, 179-185 (2011).
40. Ellner JJ. Immunoregulation in TB; observations and implications. Clin. Transl. Sci. 3, 23-28 (2010).
41. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity -friends or foes? Trends Immunol. 30, 409-411 (2009).
42. Danelishvili L, McGarvey J, Li YJ, Bermudez LE. Mycobacterium tuberculosis infection causes different levels of apoptosis and necrosis in human macrophages and alveolar epithelial cells. Cell Microbiol. 5, 649-660 (2003). (Pubitemid 37080675)
43. Ryan RC, O'Sullivan MP, Keane J. Mycobacterium tuberculosis infection induces non-apoptotic cell death of human dendritic cells. BMC Microbiol. 11, 237 (2011).
44. Gadea I, Zapardiel J, Ruiz P, Gegúndez MI, Esteban J, Soriano F. Cytopathic effect mimicking virus culture due to Mycobacterium tuberculosis. J. Clin. Microbiol. 31, 2517-2518 (1993). (Pubitemid 23254230)
45. Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun. 5, 675-690 (1992). (Pubitemid 23033002)
46. Wikipedia -Tuberculosis. http://en.wikipedia.org/wiki/Tuberculosis
47. Wikipedia -Florence B. Seibert. http://en.wikipedia.org/wiki/Florence-B.- Seibert
48. Transactions of the Sixth International Congress on Tuberculosis. http://books.google.com/books?id=ig-gAA AAMAAJ&q=calmette+therapeutic+use+ +tuberculin+washington&dq=calmette+th erapeutic+use++tuberculin+washington&h l=en&sa=X&ei=hcY2T6- zIYuXhQeri7WiAg&ved=0 CDEQ6AEwAA
49. Wikipedia -Robert Koch. http://de.wikipedia.org/wiki/Robert-Koch
50. Tubunet -treatment. www.tubunet.ru/menu2/treatment/ paragraph-3.html
51. The Nobel Prize in Physiology or Medicine 1913 -Charles Richet. www.nobelprize.org/nobel-prizes/ medicine/laureates/1913/richet-bio.html
52. The white plague: tuberculosis, man, and society. http://books.google. com.ua/books/about/ The-white-plague. html?id=DcgZbgSOPBAC&redir-esc=y
53. Classics of traditional Chinese medicine. www.nlm.nih.gov/exhibition/ chinesemedicine/emperors.html
54. The natural history of pulmonary tuberculosis, facilitator guide. www.emro.who.int/STB/media/pdf/ HARRIS+coverpage.pdf
55. Cycloferon (Polysan), St-Peterburg Russia. www.polysan-ru.com
56. Amiksin (Pharmstandart), Tomsk Russia. http://pharmstd.ru
57. Galavit (Medicor), Moscow Russia. www.medicor.ru
58. Polyoxidonium (Petrovax). Moscow Russia. www.petrovax.ru
59. Likopid (Peptec). Moscow Russia. www.licopid.ru
60. Glutoxim (Farma VAM). St-Peterburg Russia www.glutoxim.ru
61. Neovir (Pharmsynthez). St-Peterburg Russia. www.pharmsynthez.com
62. Bestim (Verta). St-Peterburg Russia. www:hpb-spb.com
63. Ronkoleukin (Biotech) St-Peterburg Russia. www.biotech.spb.ru
64. Dzherelo Immunoxel (Ekomed) Kiev, Ukraine. www.ekomed.com.ua
65. Tuberculin (SPbNIIVS -Institute of Vaccines and Sera) St-Peterburg, Russia. www.spbniivs.ru
66. V7 (Immunitor) Vancouver, Canada. www.immunitor.com